According to DelveInsight’s evaluation, the global Obsessive Compulsive Disorder (OCD) pipeline features more than 5 leading companies actively developing over 5 therapeutic candidates, with detailed analyses of clinical trials, mechanisms of action, routes of administration, and ongoing developmental progress.
DelveInsight’s report, “Obsessive Compulsive Disorder Pipeline Insight, 2025,” provides an extensive overview of the current clinical landscape and future growth potential within the Obsessive Compulsive Disorder treatment market.
The Obsessive Compulsive Disorder pipeline report delivers a thorough commercial and clinical review of pipeline therapies, covering products from early preclinical stages through advanced development. It includes detailed drug profiles highlighting mechanisms of action, clinical trial outcomes, regulatory milestones such as NDA submissions or approvals, and key product development updates involving technologies, partnerships, acquisitions, funding, designations, and related activities.
Request for Sample Report here @ Obsessive Compulsive Disorder Pipeline Insight
Some of the key takeaways from the Obsessive Compulsive Disorder Pipeline Report:
- Global pharmaceutical and biotech companies are actively advancing innovative therapies for Obsessive-Compulsive Disorder (OCD), achieving notable progress in recent years.
- Key players developing OCD treatments include Ceruvia Lifesciences, Biohaven Pharmaceuticals, Octapharma, Jazz Pharmaceuticals, Eli Lilly and Company, Spec GX (Mallinckrodt), Power Life Sciences Inc., Apotex, and several others.
- Promising emerging therapies - such as Troriluzole, SYNP-101, and additional pipeline candidates - are expected to significantly influence the Obsessive-Compulsive Disorder treatment landscape in the coming years.
- In March 2025, Biohaven Pharmaceuticals reported the initiation of a study assessing the safety and efficacy of troriluzole as an adjunct therapy versus placebo in patients with Obsessive-Compulsive Disorder.
- Also in March 2025, Yale University launched a study in which all participants receive optimized doses of the investigational drug, with the primary outcome being changes from baseline using the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) at Week 12.
- Biohaven continues to advance BHV-4157, a glutamate modulator currently in Phase 2/3 trials for OCD as of September 2024.
- COMPASS Pathways began a Phase II trial of psilocybin (COMP360) for OCD in February 2024.
- In December 2024, researchers announced results from the first-ever clinical trial using MR-guided focused ultrasound (MRgFUS) capsulotomy for treatment-resistant OCD. A 10-year follow-up showed durable symptom reduction, improved daily functioning, and high patient satisfaction - positioning MRgFUS as a safe and promising new treatment avenue for individuals who do not respond to conventional therapies.
Obsessive Compulsive Disorder Overview
Obsessive-Compulsive Disorder (OCD) is a chronic neuropsychiatric condition characterized by intrusive, unwanted thoughts (obsessions) and repetitive behaviors or mental rituals (compulsions) performed to reduce anxiety. These symptoms can significantly impair daily functioning, relationships, and quality of life. OCD often emerges in adolescence or early adulthood and typically follows a lifelong course if untreated. The disorder is linked to dysregulation in serotonin and glutamate pathways, along with genetic and environmental factors. Standard treatments include cognitive behavioral therapy (CBT), particularly exposure and response prevention (ERP), and selective serotonin reuptake inhibitors (SSRIs). Emerging therapies aim to address treatment-resistant cases.
Get a Free Sample PDF Report to know more about Obsessive Compulsive Disorder Pipeline Therapeutic Assessment- Obsessive Compulsive Disorder Treatment Drugs
Obsessive Compulsive Disorder Route of Administration
Obsessive Compulsive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Obsessive Compulsive Disorder Molecule Type
Obsessive Compulsive Disorder Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Obsessive Compulsive Disorder Pipeline Therapeutics Assessment
- Obsessive Compulsive Disorder Assessment by Product Type
- Obsessive Compulsive Disorder By Stage and Product Type
- Obsessive Compulsive Disorder Assessment by Route of Administration
- Obsessive Compulsive Disorder By Stage and Route of Administration
- Obsessive Compulsive Disorder Assessment by Molecule Type
- Obsessive Compulsive Disorder by Stage and Molecule Type
Request for Sample PDF Report for Obsessive Compulsive Disorder Pipeline Assessment and clinical trials - Obsessive Compulsive Disorder Medication and Drugs
DelveInsight’s Obsessive Compulsive Disorder (OCD) report highlights more than five therapeutic candidates progressing through various stages of clinical development, including:
- Phase III (late-stage) therapies
- Phase II (mid-stage) candidates
- Phase I (early-stage) programs
- Preclinical and discovery-level molecules
- Discontinued and inactive assets
- Multiple routes of administration
Obsessive Compulsive Disorder Therapeutic Landscape
Key therapies currently under development or evaluation include:
- Troriluzole – Biohaven Pharmaceuticals, Inc.
- Fluvoxamine Maleate – AbbVie
- BHV-4157 – Biohaven Pharmaceuticals, Inc.
- Quetiapine – AstraZeneca
- Reclaim® – MedtronicNeuro
- Bitopertin – Hoffmann-La Roche
- Topiramate – Ortho-McNeil Pharmaceutical
- Escitalopram – Forest Laboratories
- Duloxetine – Eli Lilly and Company
- Topiramate – Janssen-Ortho Inc.
- Paliperidone – Ortho-McNeil Janssen Scientific
- Pregabalin – Pfizer
Obsessive Compulsive Disorder Pipeline Analysis:
The Obsessive Compulsive Disorder pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Obsessive Compulsive Disorder with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obsessive Compulsive Disorder Treatment.
- Obsessive Compulsive Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Obsessive Compulsive Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obsessive Compulsive Disorder market.
Download Sample PDF Report to know more about Obsessive Compulsive Disorder drugs and therapies- Obsessive Compulsive Disorder Clinical Trials and Recent Developments
Obsessive Compulsive DisorderMarket Drivers
- Rising diagnosed patient population:Increasing awareness and improved diagnostic capabilities are leading to higher identification of OCD cases globally.
- Unmet medical needs:Many patients do not respond adequately to existing therapies, creating demand for more effective treatment options.
- Advancements in neuroscience and psychopharmacology:Better understanding of neurocircuitry and neurotransmitter pathways is enabling the development of innovative drugs and neuromodulation therapies.
- Growing adoption of digital therapeutics and behavioral interventions:Technology-enabled CBT, telemedicine, and remote monitoring are enhancing access to care.
- Strong pipeline activity:Emerging therapies such as glutamate modulators, psychedelic-assisted treatments, and neuromodulation techniques are attracting significant R&D investments.
- Supportive regulatory environment:Orphan designations, fast-track approvals, and increasing FDA/EMA interest in psychiatric innovations are accelerating clinical development.
Obsessive Compulsive DisorderMarket Barriers
- Treatment resistance remains high:A substantial proportion of patients do not achieve adequate symptom relief with available therapies.
- Complex disease biology:Heterogeneous symptoms and multifactorial causes make drug development more challenging.
- Side effects of current medications:SSRIs, antipsychotics, and other existing drugs often cause adverse effects, impacting adherence.
- Stigma and underdiagnosis:Social stigma and limited mental health literacy still delay diagnosis and treatment in several regions.
- Limited access to advanced therapies:High costs and restricted availability of specialized treatments (e.g., deep brain stimulation, MRgFUS, psychedelic therapies) constrain adoption.
- Regulatory and ethical challenges:Psychedelic-based treatment development faces additional scrutiny, slowing market entry.
Scope of Obsessive Compulsive Disorder Pipeline Drug Insight
- Geographical Scope: Global
- Leading Companies in Obsessive-Compulsive Disorder: Ceruvia Lifesciences, Biohaven Pharmaceuticals, Octapharma, Jazz Pharmaceuticals, Eli Lilly and Company, Spec GX (Mallinckrodt), Power Life Sciences Inc., Apotex, among others.
- Prominent OCD Therapies: Troriluzole, SYNP 101, along with additional emerging candidates.
- Therapeutic Evaluation: Includes both currently available treatments and pipeline therapies for Obsessive–Compulsive Disorder.
- Market Dynamics: Encompasses key factors driving the OCD market as well as major challenges and barriers impacting growth.
Further Obsessive Compulsive Disorder product details are provided in the report. Download the Obsessive Compulsive Disorder pipeline report to learn more about the emerging Obsessive Compulsive Disorder therapies- Obsessive Compulsive Disorder FDA Approvals and Therapeutic Assessment
Table of Contents
1. Obsessive Compulsive Disorder Report Introduction
2. Obsessive Compulsive Disorder Executive Summary
3. Obsessive Compulsive Disorder Overview:
4. Obsessive Compulsive Disorder- Analytical Perspective In-depth Commercial Assessment
5. Obsessive Compulsive Disorder Pipeline Therapeutics
6. Obsessive Compulsive Disorder Late Stage Products (Phase II/III)
7. Obsessive Compulsive Disorder Mid Stage Products (Phase II)
8. Obsessive Compulsive Disorder Early Stage Products (Phase I)
9. Obsessive Compulsive Disorder Preclinical Stage Products
10. Obsessive Compulsive Disorder Therapeutics Assessment
11. Obsessive Compulsive Disorder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Obsessive Compulsive Disorder Companies
14. Obsessive Compulsive Disorder Key Products
15. Obsessive Compulsive Disorder Unmet Needs
16 . Obsessive Compulsive Disorder Market Drivers and Barriers
17. Obsessive Compulsive Disorder Future Perspectives and Conclusion
18. Obsessive Compulsive Disorder Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services